[1]艾迎春,迟男男,杜景峰,等.芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及 抑制因子的影响[J].医学信息,2018,31(15):140-142.[doi:10.3969/j.issn.1006-1959.2018.15.045]
　AI Ying-chun,CHI Nan-nan,DU Jing-feng,et al.Effects of Qishenerlian Decoction on Matrix Metalloproteinase-1 and Its Inhibitory Factors in Rats with Hepatic Fibrosis[J].Journal of Medical Information,2018,31(15):140-142.[doi:10.3969/j.issn.1006-1959.2018.15.045]
点击复制

芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及 抑制因子的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年15期
页码:
140-142
栏目:
中医中药
出版日期:
2018-08-01

文章信息/Info

Title:
Effects of Qishenerlian Decoction on Matrix Metalloproteinase-1 and Its Inhibitory Factors in Rats with Hepatic Fibrosis
文章编号:
1006-1959（2018）15-0140-03
作者:
艾迎春; 迟男男; 杜景峰; 张雪梅
佳木斯大学附属第一医院消化二科，黑龙江 佳木斯 154002
Author(s):
AI Ying-chun; CHI Nan-nan; DU Jing-feng; ZHANG Xue-mei
Department of Digestion,Subject Two,the First Affiliated Hospital of Jiamusi University,Jiamusi 154002,Heilongjiang,China
关键词:
芪参二莲汤; 肝纤维化; 基质金属蛋白酶-1; 抑制因子
Keywords:
Key words：Qishenerlian Decoction; Hepatic fibrosis; Matrix metalloproteinase-1; Inhibitory factors
分类号:
R285.5
DOI:
10.3969/j.issn.1006-1959.2018.15.045
文献标志码:
A
摘要:
目的 研究不同剂量芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及抑制因子变化的影响。方法 于2017年6月~8月选择90只SD雄性大鼠作为研究对象，按照体质量随机分为6组，每组15只，其中1组为正常组，其余5组均为肝纤维化模型，将其分为模型组、秋水仙碱组以及芪参二莲汤低剂量组（5 g/kg）、中剂量组（10 g/kg）和高剂量组（15 g/kg）；各给药组分别给予相应的药物灌胃，正常组、模型组则给予生理盐水灌胃；对比各组大鼠MMP-1和TIMP-1水平以及肝纤维化指标水平。结果 正常组与模型组比较，后者的MMP-1、MMP-1/TIMP-1水平明显降低，而TLISA-1水平则明显升高，差异有统计学意义（P＜0.05）；模型组与各给药组比较，各给药组的MMP-1、MMP-1/TIMP-1水平较模型组升高，而TIMP-1水平则较模型组降低，差异有统计学意义（P＜0.05），且给药组中，以芪参二莲汤高剂量组的变化水平最为显著，差异有统计学意义（P＜0.05）。结论 15 g/kg高剂量的芪参二莲汤用于治疗肝纤维化大鼠，能够有效促进MMP-1表达、减少TIMP-1表达，进而起到逆转肝纤维化的作用。
Abstract:
Abstract：Objective To study the effects of different doses of Qishenerlian Decoction on matrix metalloproteinase-1 and inhibitor of hepatic fibrosis in rats.Methods In June to August 2017, 90 male SD rats were selected as the research subjects.According to the body mass,they were randomly divided into 6 groups,with 15 rats in each group,of which 1 was the normal group and the other 5 groups were liver fibrosis models.They were divided into model group,colchicine group and low dose group of Qishenerlian Decoction (5g/kg),medium dose group(10g/kg)and high dose group(15g/kg).Each drug-administered group was given the corresponding drugs,and the normal group and the model group were given normal saline.The levels of MMP-1 and TIMP-1 and liver fibrosis were compared between the groups.Results Compared with the normal group,the level of MMP-1 and MMP-1/TIMP-1 in the model group was significantly decreased,while the level of TLISA-1 was significantly higher,the difference was statistically significant(P<0.05);Compared with the drug-administered group,the MMP-1 and MMP-1/TIMP-1 levels in the model group were higher than those in the model group,while the TIMP-1 level was lower than that in the model group,the difference was statistically significant(P<0.05),and in the drug-administered group,the change level of the high-dose group of Qishenerlian Decoction was the most significant,and the difference was statistically significant(P<0.05).Conclusion The high dose Qishenerlian Decoction for 15g/kg can effectively promote the expression of MMP-1,reduce the expression of TIMP-1 and reverse the hepatic fibrosis in rats.

参考文献/References:

[1]袁星星,郭蕾,王炳予,等.芪参二莲汤对肝纤维化大鼠血清基质金属蛋白酶-1及其抑制剂-1水平的影响[J].中国中医药信息杂志,2017,24(05):52-56.
[2]山丹,巴图德力根.肝纤维化与MMPs及TIMPs的研究进展[J].中国民族民间医药,2015,24(05):39-40.
[3]王振常,杨删,黄晶晶,等.柔肝化纤颗粒对CCl_4诱导的肝纤维化大鼠肝脏MMP-2、TIMP-2的影响[J].疑难病杂志,2014,13(01):74-76,82.

相似文献/References:

[1]王艳欣,孟庆华,朱跃科.非侵入性检查方法评价肝纤维化的研究进展[J].医学信息,2018,31(03):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
　WANG Yan-xin,MENG Qing-hua,ZHU Yue-ke.Progress in Evaluation of Liver Fibrosis by Non-invasive Methods[J].Journal of Medical Information,2018,31(15):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
[2]李顶春,李 武.Wnt信号通路与肝纤维化[J].医学信息,2018,31(09):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
　LI Ding-chun,LI Wu.Wnt Signaling Pathway and Hepatic Fibrosis[J].Journal of Medical Information,2018,31(15):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
[3]董 朴,蔡福景,张 东,等.胆维他片对肝纤维化大鼠肝中抗氧化体系的影响[J].医学信息,2019,32(18):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
　DONG Pu,CAI Fu-jing,ZHANG Dong,et al.Effect of Danweiita Tablet on Antioxidant System in Liver of Rats with Hepatic Fibrosis[J].Journal of Medical Information,2019,32(15):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
[4]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
　PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[5]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
　LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Journal of Medical Information,2019,32(15):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[6]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
　ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Journal of Medical Information,2020,33(15):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
[7]邹克平.超声实时剪切波弹性成像对血吸虫病肝纤维化的诊断效能分析[J].医学信息,2022,35(18):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
　ZOU Ke-ping.Analysis of Diagnostic Efficacy of Ultrasound Shear Wave Elastography in Schistosomiasis Liver Fibrosis[J].Journal of Medical Information,2022,35(15):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
[8]郭 冶,卢凤美,刘东璞.肝纤维化发病机制及大黄酸对肝纤维化的作用[J].医学信息,2020,33(12):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
　GUO Ye,LU Feng-mei,LIU Dong-pu.The Pathogenesis of Hepatic Fibrosis and the Effect of Rhein on Hepatic Fibrosis[J].Journal of Medical Information,2020,33(15):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
[9]徐勇平.舒肝宁注射液治疗晚期血吸虫病肝纤维化的效果及其对血清指标的影响[J].医学信息,2020,33(24):151.[doi:10.3969/j.issn.1006-1959.2020.24.043]
　XU Yong-ping.Shuganning Injection in the Treatment of Advanced Schistosomiasis Liver Fibrosis and Its Influence on Serum Indexes[J].Journal of Medical Information,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.24.043]
[10]叶 亮,赵永忠.FIB-4、APRI及肝纤维指标对乙型肝炎肝硬化的诊断价值[J].医学信息,2021,34(05):85.[doi:10.3969/j.issn.1006-1959.2021.05.024]
　YE Liang,ZHAO Yong-zhong.The Diagnostic Value of FIB-4,APRI and Liver Fiber Indexes in Hepatitis B Liver Cirrhosis[J].Journal of Medical Information,2021,34(15):85.[doi:10.3969/j.issn.1006-1959.2021.05.024]

更新日期/Last Update: 2018-08-01